Morning Watch List: Loxo Oncology, Inc. (NASDAQ:LOXO), Enzymotec Ltd. (NASDAQ:ENZY), WSFS Financial Corp. (NASDAQ:WSFS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Tesla Motors Inc (NASDAQ:TSLA)

Loxo Oncology, Inc. (NASDAQ:LOXO) belongs to Healthcare sector. Its weekly performance is -11.98%. On last trading day company shares ended up $17.12. Loxo Oncology, Inc. (NASDAQ:LOXO) distance from 50-day simple moving average (SMA50) is 21.56%. Loxo Oncology, Inc. (NASDAQ:LOXO) announced that Joshua H. Bilenker, M.D., chief executive officer, presented a corporate overview at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 24, 2015 at 11:30AM Eastern Time.

Enzymotec Ltd. (NASDAQ:ENZY) shares advanced 1.60% in last trading session and ended the day at $8.25. ENZY Gross Margin is 61.10% and its return on assets is 3.20%. Enzymotec Ltd. (NASDAQ:ENZY) quarterly performance is 7.84%. Enzymotec Ltd. (NASDAQ:ENZY) announced that it will hold an Annual General Meeting of Shareholders on Wednesday, July 29, 2015. The record date for shareholders entitled to vote at the meeting is Friday, June 19, 2015.

On 02 July, WSFS Financial Corp. (NASDAQ:WSFS) shares decreased -1.29% and was closed at $27.45. WSFS EPS growth in last 5 year was 83.80%. WSFS Financial Corp. (NASDAQ:WSFS) year to date (YTD) performance is 7.52%. WSFS Financial Corp. (NASDAQ:WSFS) announced the product introduction of WSFS Mobile Cash, a service that allows Customers to securely withdraw cash from an ATM by using their WSFS Mobile Banking app. WSFS will be the fourth bank in the United States to offer the service.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) belongs to Healthcare sector. Its weekly performance is 2.27%. On last trading day company shares ended up $131.26. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) distance from 50-day simple moving average (SMA50) is 3.79%. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Thursday that the U.S. Food and Drug Administration has approved Orkambi, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. Cystic fibrosis is a rare, life-threatening genetic disease. People with two copies of the F508del mutation represent the largest group of people with cystic fibrosis. Of the 30,000 people in the United States with cystic fibrosis, about 8,500 ages 12 and older have two copies of the F508del mutation.
Tesla Motors Inc (NASDAQ:TSLA) shares advanced 4.04% in last trading session and ended the day at $280.02. TSLA Gross Margin is 28.00% and its return on assets is -8.00%. Tesla Motors Inc (NASDAQ:TSLA) quarterly performance is 46.61%. Tesla Motors Inc (NASDAQ:TSLA) beat its car-sales forecast for the second consecutive quarter with a 52 percent surge in the three months through June. Tesla delivered 11,507 Model S sedans in the period, the Palo Alto, California-based manufacturer said Thursday in a statement of preliminary figures. The company predicted in May that it would sell 10,000 to 11,000 of the electric-powered car, its only model, during the second quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *